Study wrapper · #829
Glucagon-Like Peptide-1 Based Therapies and the Risk of Severe Gastrointestinal Motility Adverse Events: A Cohort Study.
Editor's note
A large, well-constructed active-comparator cohort (313,342 matched pairs) examining a real and above-the-fold safety question: severe gastrointestinal motility events — constipation, gastroparesis, bowel obstruction — with GLP-1-based therapies. Tirzepatide is explicitly included in the exposure arm, though most of the analysis is at the class level versus SGLT-2 inhibitors. The reported signal is consistent: a 37% relative increase in the composite outcome (HR 1.37, 95% CI 1.30–1.45), stable across agent, age, sex, BMI, frailty and opioid-use subgroups. The crucial framing, which the authors handle well, is absolute risk: even elevated, the event rate was about 1 per 100 person-years or less — roughly 1% — so the relative increase sits on a small base. The new-user, active-comparator design and propensity matching are methodological strengths that reduce (though cannot eliminate) confounding by indication. A credible, clinically useful safety data point that belongs on the risk side of the ledger, with the relative-versus-absolute distinction made plain.
Plain-language abstract
This large study examined a known type of side effect from GLP-1 medications: serious problems with how the gut moves food along, including severe constipation, a condition called gastroparesis (where the stomach empties too slowly), and bowel blockages. Researchers used U.S. health-insurance databases to compare more than 300,000 pairs of people with type 2 diabetes — one group starting a GLP-1-based drug (including tirzepatide) and a closely matched group starting a different diabetes drug (an SGLT-2 inhibitor). Over about five months of follow-up, the GLP-1 group had a higher rate of these gut problems: about 1 case per 100 people per year versus about 0.75 in the comparison group, a 37% higher relative risk that held steady across different ages, sexes, and other groupings. The key context is that the overall risk stayed low — around 1% or less — so while the increase is real and consistent, it sits on a small baseline. The study's careful design, comparing new users of similar-purpose drugs, strengthens confidence, though it observed patients rather than randomly assigning treatment. This is useful information for weighing the digestive risks of these medications.